RS60558B1 - Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost - Google Patents

Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost

Info

Publication number
RS60558B1
RS60558B1 RS20200860A RSP20200860A RS60558B1 RS 60558 B1 RS60558 B1 RS 60558B1 RS 20200860 A RS20200860 A RS 20200860A RS P20200860 A RSP20200860 A RS P20200860A RS 60558 B1 RS60558 B1 RS 60558B1
Authority
RS
Serbia
Prior art keywords
oral bioavailability
macrocyclic ring
pentaaza macrocyclic
ring complexes
complexes possessing
Prior art date
Application number
RS20200860A
Other languages
English (en)
Inventor
Jeffery L Keene
Otto F Schall
Dennis P Riley
Original Assignee
Galera Labs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galera Labs Llc filed Critical Galera Labs Llc
Publication of RS60558B1 publication Critical patent/RS60558B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005Compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00Compounds containing elements of Groups 1 or 11 of the Periodic System
    • C07F1/08Copper compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/02Iron compounds
    • C07F15/025Iron compounds without a metal-carbon linkage
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/04Nickel compounds
    • C07F15/045Nickel compounds without a metal-carbon linkage
RS20200860A 2015-08-11 2016-08-11 Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost RS60558B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562203761P 2015-08-11 2015-08-11
EP16835928.9A EP3334744B1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability
PCT/US2016/046599 WO2017027728A1 (en) 2015-08-11 2016-08-11 Pentaaza macrocyclic ring complexes possessing oral bioavailability

Publications (1)

Publication Number Publication Date
RS60558B1 true RS60558B1 (sr) 2020-08-31

Family

ID=57984526

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200860A RS60558B1 (sr) 2015-08-11 2016-08-11 Pentaaza makrociklični prstenasti kompleksi koji poseduju oralnu bioraspoloživost

Country Status (29)

Country Link
US (5) US10597415B2 (sr)
EP (2) EP3738967A1 (sr)
JP (3) JP7041959B2 (sr)
KR (1) KR20180064380A (sr)
CN (3) CN113416170A (sr)
AU (3) AU2016306568B2 (sr)
CA (1) CA2994845A1 (sr)
CL (1) CL2018000371A1 (sr)
CO (1) CO2018002544A2 (sr)
CY (1) CY1123960T1 (sr)
DK (1) DK3334744T3 (sr)
EA (1) EA201890471A1 (sr)
ES (1) ES2807528T3 (sr)
HK (1) HK1257313A1 (sr)
HR (1) HRP20201092T1 (sr)
HU (1) HUE049926T2 (sr)
IL (3) IL297735B1 (sr)
LT (1) LT3334744T (sr)
MX (2) MX2018001605A (sr)
MY (1) MY196401A (sr)
PH (1) PH12018500296A1 (sr)
PL (1) PL3334744T3 (sr)
PT (1) PT3334744T (sr)
RS (1) RS60558B1 (sr)
SG (1) SG10202002859QA (sr)
SI (1) SI3334744T1 (sr)
UA (1) UA126788C2 (sr)
WO (1) WO2017027728A1 (sr)
ZA (2) ZA201801546B (sr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
EA201890471A1 (ru) 2015-08-11 2018-10-31 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью
CN109906081A (zh) 2016-09-01 2019-06-18 加莱拉实验室有限责任公司 利用五氮杂大环络合物和抗坏血酸类化合物的联合癌症疗法
WO2018152353A2 (en) 2017-02-15 2018-08-23 Galera Labs, Llc Pentaaza macrocyclic ring complexes for local intestinal delivery
CA3059581A1 (en) * 2017-04-13 2018-10-18 Galera Labs, Llc Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
JP2022551494A (ja) * 2019-10-10 2022-12-09 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー マンガン含有配位錯体の水性製剤の製造方法、製剤および処置方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
ES2113952T3 (es) * 1991-07-19 1998-05-16 Monsanto Co Complejos de manganeso con ligandos macrociclicos nitrogenados eficaces como catalizadores para dismutar superoxidos.
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
US6204259B1 (en) * 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1995028968A1 (en) 1994-04-22 1995-11-02 Monsanto Company Diagnostic image analysis with metal complexes
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
CA2229781A1 (en) 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US6180620B1 (en) 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
AU737650B2 (en) 1997-11-03 2001-08-23 Duke University Substituted porphyrins
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
JP2003500174A (ja) 1999-05-27 2003-01-07 フアルマシア・コーポレーシヨン スーパーオキシド・ジスムターゼ模倣体で修飾された生体材料
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
AU2001236798B2 (en) 2000-02-08 2004-11-04 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
EP1347773B1 (en) 2001-01-05 2010-04-14 Metaphore Pharmaceuticals Inc. Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines
DE60233317D1 (de) 2001-01-19 2009-09-24 Nat Jewish Med & Res Center Medikament zum schutz in der radiotherapie
WO2002058686A2 (en) 2001-01-26 2002-08-01 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
ES2541768T3 (es) * 2001-03-02 2015-07-24 Galera Therapeutics Llc Cromatografía de complejos metálicos
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
PL216750B1 (pl) 2001-11-01 2014-05-30 Uab Research Foundation Zastosowanie przeciwciał selektywnych dla receptora liganda indukującego apoptozę pokrewnego czynnikowi martwicy nowotworu i innych czynników terapeutycznych do leczenia nowotworu oraz kompozycja zawierająca takie przeciwciała i inne czynniki terapeutyczne
AU2003229923A1 (en) 2002-04-16 2003-11-03 Isis Innovation Limited Curcumin for the prevention and/or treatment of tissue damage
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
GB0412893D0 (en) * 2004-06-10 2004-07-14 Univ Hull Novel antiviral macrocycle derivatives and metal complexes, incorporating bridged macrocycles
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) * 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20090099150A1 (en) 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
EP1863778B1 (en) 2005-03-31 2015-12-30 Merck Sharp & Dohme Corp. Spirocyclic thrombin receptor antagonists
EP2020998A4 (en) 2006-05-23 2010-07-21 Univ Utah Res Found COMPOSITIONS AND METHODS OF INHIBITING THE ENDOTHELIAL STAIN OXIDE SYNTHASE ACTIVITY
WO2008027547A2 (en) 2006-08-31 2008-03-06 The Brigham And Women's Hospital, Inc. Antioxidant therapies
LT2056675T (lt) * 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
US8486928B2 (en) * 2007-11-14 2013-07-16 Galera Therapeutics Super-oxide dismutase mimetics
WO2009111294A1 (en) 2008-02-29 2009-09-11 Eagle Pharmaceuticals, Inc. Topotecan ready to use solutions
JP2011516610A (ja) 2008-04-15 2011-05-26 インターミューン・インコーポレーテッド C型肝炎ウイルス複製の新規な阻害剤
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
US8642557B2 (en) 2010-03-12 2014-02-04 Abbvie Biotherapeutics Inc. CTLA4 proteins and their uses
WO2013048965A1 (en) 2011-09-26 2013-04-04 Galera Therapeutics, Llc Methods for treatment of diseases
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
EA201890471A1 (ru) 2015-08-11 2018-10-31 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комплексные соединения, содержащие макроциклическое кольцо пентаазы, обладающие пероральной биодоступностью
KR20230075528A (ko) 2016-05-03 2023-05-31 갈레라 랩스, 엘엘씨 암 치료를 위한 조합 요법

Also Published As

Publication number Publication date
CN108350009A (zh) 2018-07-31
US9738670B2 (en) 2017-08-22
JP2024012401A (ja) 2024-01-30
DK3334744T3 (da) 2020-07-27
CN113416170A (zh) 2021-09-21
IL287546A (en) 2021-12-01
ES2807528T3 (es) 2021-02-23
MY196401A (en) 2023-03-29
HK1257313A1 (zh) 2019-10-18
US9738669B2 (en) 2017-08-22
HRP20201092T1 (hr) 2020-10-30
AU2016306568A1 (en) 2018-03-22
EA201890471A1 (ru) 2018-10-31
ZA201801546B (en) 2020-07-29
CO2018002544A2 (es) 2018-07-10
CL2018000371A1 (es) 2018-08-03
PT3334744T (pt) 2020-07-28
MX2022010230A (es) 2022-09-19
IL257346A (en) 2018-03-29
US11066433B2 (en) 2021-07-20
ZA202001373B (en) 2021-10-27
CY1123960T1 (el) 2022-03-24
US20200223879A1 (en) 2020-07-16
IL257346B (en) 2021-12-01
CA2994845A1 (en) 2017-02-16
SG10202002859QA (en) 2020-05-28
US20180237462A1 (en) 2018-08-23
CN108350009B (zh) 2021-07-09
LT3334744T (lt) 2020-07-27
IL287546B2 (en) 2023-04-01
IL297735B1 (en) 2024-04-01
AU2023200738A1 (en) 2023-03-09
JP2022023183A (ja) 2022-02-07
UA126788C2 (uk) 2023-02-08
IL287546B (en) 2022-12-01
WO2017027728A1 (en) 2017-02-16
MX2018001605A (es) 2018-09-26
EP3334744B1 (en) 2020-04-22
PH12018500296A1 (en) 2018-08-13
US20170044193A1 (en) 2017-02-16
EP3334744A1 (en) 2018-06-20
SI3334744T1 (sl) 2020-10-30
AU2020289730A1 (en) 2021-01-21
US10597415B2 (en) 2020-03-24
EP3334744A4 (en) 2019-03-06
IL297735A (en) 2022-12-01
US20170042907A1 (en) 2017-02-16
PL3334744T3 (pl) 2020-09-21
CN113402560A (zh) 2021-09-17
HUE049926T2 (hu) 2020-11-30
WO2017027728A9 (en) 2017-04-06
US20210347796A1 (en) 2021-11-11
JP7041959B2 (ja) 2022-03-25
KR20180064380A (ko) 2018-06-14
JP2018525388A (ja) 2018-09-06
EP3738967A1 (en) 2020-11-18
AU2020289730B2 (en) 2022-11-10
AU2016306568B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
IL287546A (en) Macrocyclic ring pentase complexes with oral bioavailability
AU365267S (en) Ring
TWD174458S (zh) 戒指
GB2532789B (en) Absolute rotary encoder
ZA201607765B (en) Novel macrocyclic compounds
GB201512967D0 (en) Rotary encoder
IL256205B (en) Positional encoder
EP3382222A4 (en) ROTATION RING
EP3338805A4 (en) Drug complex
GB201602090D0 (en) Powder
HK1210657A2 (en) Ring sizer
GB2550216B (en) Teething Ring
GB201615916D0 (en) Pharmaceutical compound
GB201615912D0 (en) Pharmaceutical compound
GB201715210D0 (en) Macrocyclic compounds
AU201812909S (en) Ring
GB201704121D0 (en) Macrocyclic compounds
GB201704125D0 (en) Macrocyclic Compounds
GB201720326D0 (en) Nimb Ring
AU201715227S (en) Ring
AU201715228S (en) Ring
AU201613163S (en) Ring
TWM533982U (en) Rotary bed structure
GB201602861D0 (en) Pharmaceutical compounds
GB201508224D0 (en) Teething ring